The U.S. Food and Drug Administration announced it will consolidate multiple adverse-event reporting systems into a single Adverse Event Monitoring System (AEMS). The agency said the unified platform will centralize safety signals for drugs, vaccines and other regulated products, replacing disparate legacy databases. The move is intended to improve transparency, reduce operating costs and streamline cross-center monitoring workflows. Officials emphasized that AEMS will aggregate unverified reports and does not change the evidentiary standard for causation; reports still require follow-up and adjudication. The consolidation echoes the FDA's broader transparency push and aligns with recent statutory and operational efforts to modernize pharmacovigilance. Stakeholders from industry and patient-advocacy groups will watch implementation closely, because data harmonization and analytic pipelines will determine whether the new system accelerates signal detection without increasing false positives.